GSE229663 GSE229666 menin inhibition 3 v 2 human up (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE229663_GSE229666_menin inhibition_3_v_2_human_up.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE229663_GSE229666_menin inhibition_3_v_2_human_up.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE229663_GSE229666_menin inhibition_3_v_2_human_up.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE229663_GSE229666_menin inhibition_3_v_2_human_up.

Results found

Linked to

 

Label

Description

 

Gene

H4 clustered histone 15

Gene

family with sequence similarity 30 member A

Gene

HLA complex P5

Gene

maternally expressed 3

Gene

H3 clustered histone 7

Gene

tripartite motif containing 16 like (pseudogene)

Gene

PAX8 antisense RNA 1

Gene

long intergenic non-protein coding RNA 665

Gene

double homeobox A pseudogene 8

Gene

general transcription factor IIi pseudogene 4

  • Gene

    H4 clustered histone 15


  • Gene

    family with sequence similarity 30 member A



  • Gene

    maternally expressed 3


  • Gene

    H3 clustered histone 7


  • Gene

    tripartite motif containing 16 like (pseudogene)


  • Gene

    PAX8 antisense RNA 1


  • Gene

    long intergenic non-protein coding RNA 665


  • Gene

    double homeobox A pseudogene 8


  • Gene

    general transcription factor IIi pseudogene 4

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.